- Recruiting
NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Sponsor
ClinicalTrials.gov Identifier: NCT05463939
Official Title: Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
First Posted : July 19, 2022
Click here to see details on ClinicalTrials.gov